

## **Moxifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.04.2023

 2.9
 30.09.2023
 1731718-00013
 Date of first issue: 05.06.2017

#### **SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Moxifloxacin Liquid Formulation

Manufacturer or supplier's details

Company name of supplier : MSD

Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

**GHS Classification** 

Reproductive toxicity : Category 2

**GHS** label elements

Hazard pictograms



Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P280 Wear protective gloves/ protective clothing/ eye protection/

face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste dis-

posal plant.

Other hazards

None known.



## **Moxifloxacin Liquid Formulation**

Date of last issue: 26.04.2023 Version Revision Date: SDS Number: 2.9 30.09.2023 1731718-00013 Date of first issue: 05.06.2017

#### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	>= 0.1 -<= 0.2

#### **SECTION 4. FIRST AID MEASURES**

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse. : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting. If swallowed

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

In case of eye contact

delayed

Suspected of damaging the unborn child.

Protection of first-aiders First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician Treat symptomatically and supportively.

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

No hazardous combustion products are known

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do



## **Moxifloxacin Liquid Formulation**

Date of last issue: 26.04.2023 Version Revision Date: SDS Number: 2.9 30.09.2023 1731718-00013 Date of first issue: 05.06.2017

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions** Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material

can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation. Avoid inhalation of vapor or mist.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Take care to prevent spills, waste and minimize release to the

environment.

If exposure to chemical is likely during typical use, provide eye Hygiene measures

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures,



## **Moxifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.04.2023

 2.9
 30.09.2023
 1731718-00013
 Date of first issue: 05.06.2017

industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Gases

#### **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Moxifloxacin HCL	186826-86-8	TWA	1000 μg/m3 (OEB 1)	Internal

**Engineering measures** : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : liquid

Color : yellow

Odor : odorless

Odor Threshold : No data available

pH : 4.1 - 4.6



## **Moxifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.04.2023

 2.9
 30.09.2023
 1731718-00013
 Date of first issue: 05.06.2017

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : 1.0044 g/cm³ (20 °C)

Solubility(ies)

Water solubility : slightly soluble

Partition coefficient: n-

octanol/water

No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- : Can react with strong oxidizing agents.



## **Moxifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.04.2023

 2.9
 30.09.2023
 1731718-00013
 Date of first issue: 05.06.2017

tions

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

#### Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

## **Acute toxicity**

Not classified based on available information.

#### **Components:**

### **Moxifloxacin HCL:**

Acute oral toxicity : LD50 (Rat): 1,320 mg/kg

LD50 (Mouse): > 435 mg/kg

LD50 (Monkey): 1,500 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

#### **Moxifloxacin HCL:**

Species : Rabbit

Result : No skin irritation

## Serious eye damage/eye irritation

Not classified based on available information.

### **Components:**

## **Moxifloxacin HCL:**

Species : Rabbit

Result : Moderate eye irritation

## Respiratory or skin sensitization

## Skin sensitization

Not classified based on available information.

### Respiratory sensitization

Not classified based on available information.

## Germ cell mutagenicity

Not classified based on available information.



## **Moxifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.04.2023

 2.9
 30.09.2023
 1731718-00013
 Date of first issue: 05.06.2017

**Components:** 

**Moxifloxacin HCL:** 

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: positive

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: in vitro micronucleus test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay)
Application Route: Oral

Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging the unborn child.

**Components:** 

**Moxifloxacin HCL:** 

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: LOAEL: 500 mg/kg body weight

Result: Effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Monkey Application Route: Oral

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: negative

Test Type: Embryo-fetal development

Species: Rabbit

Application Route: Intravenous injection

Developmental Toxicity: LOAEL: 20 mg/kg body weight

Symptoms: Skeletal malformations.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT-single exposure

Not classified based on available information.



## **Moxifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.04.2023

 2.9
 30.09.2023
 1731718-00013
 Date of first issue: 05.06.2017

## STOT-repeated exposure

Not classified based on available information.

#### Components:

#### **Moxifloxacin HCL:**

Target Organs : Liver

Assessment : May cause damage to organs through prolonged or repeated

exposure.

## Repeated dose toxicity

## **Components:**

#### **Moxifloxacin HCL:**

Species : Rat

LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

Species : Rat

NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Liver

Symptoms : Liver disorders

Species : Rat
NOAEL : 20 mg/kg
Application Route : Oral
Exposure time : 6 Months
Target Organs : Liver

Symptoms : Liver disorders

Species : Monkey
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

Symptoms : No adverse effects.

Species : Monkey
NOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 13 Weeks

Target Organs : Gastrointestinal tract

Symptoms : Vomiting

Species : Monkey
Application Route : Oral
Exposure time : 26 Weeks
Target Organs : Liver

Symptoms : Liver disorders



## **Moxifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.04.2023

 2.9
 30.09.2023
 1731718-00013
 Date of first issue: 05.06.2017

#### **Aspiration toxicity**

Not classified based on available information.

#### **Experience with human exposure**

### **Components:**

### **Moxifloxacin HCL:**

Ingestion : Symptoms: Nausea, Abdominal pain, Headache, Dizziness,

central nervous system effects, joint pain

#### **SECTION 12. ECOLOGICAL INFORMATION**

#### **Ecotoxicity**

No data available

## Persistence and degradability

No data available

## **Bioaccumulative potential**

No data available

## Mobility in soil

No data available

#### Other adverse effects

No data available

## **SECTION 13. DISPOSAL CONSIDERATIONS**

#### **Disposal methods**

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14. TRANSPORT INFORMATION**

## International Regulations

#### **UNRTDG**

Not regulated as a dangerous good

#### **IATA-DGR**

Not regulated as a dangerous good

#### **IMDG-Code**

Not regulated as a dangerous good

## Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### **Domestic regulation**

#### NOM-002-SCT

Not regulated as a dangerous good



## **Moxifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.04.2023

 2.9
 30.09.2023
 1731718-00013
 Date of first issue: 05.06.2017

## Special precautions for user

Not applicable

#### **SECTION 15. REGULATORY INFORMATION**

# Safety, health and environmental regulations/legislation specific for the substance or mixture

Federal Law for the control of chemical precursors, : Not applicable essential chemical products and machinery for

producing capsules, tablets and pills.

#### The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### **SECTION 16. OTHER INFORMATION**

Revision Date : 30.09.2023 Date format : dd.mm.yyyy

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk, IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Sub-



## **Moxifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.04.2023

 2.9
 30.09.2023
 1731718-00013
 Date of first issue: 05.06.2017

stances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8